Bioventus (NYSE:BVS) Reaches New 12-Month High at $11.52

Bioventus Inc. (NYSE:BVS)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $11.52 and last traded at $11.52, with a volume of 1104 shares. The stock had previously closed at $11.17.

Analyst Ratings Changes

Several analysts have weighed in on the company. Canaccord Genuity Group raised their price target on Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Craig Hallum raised their target price on shares of Bioventus from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th.

Bioventus Stock Up 2.8 %

The company has a quick ratio of 0.96, a current ratio of 1.33 and a debt-to-equity ratio of 1.82. The stock has a 50-day simple moving average of $8.47 and a two-hundred day simple moving average of $6.54. The firm has a market cap of $900.12 million, a PE ratio of -32.49 and a beta of 0.89.

Bioventus (NYSE:BVS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.12. The company had revenue of $151.22 million for the quarter, compared to analysts’ expectations of $137.70 million. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. During the same period last year, the firm posted $0.14 EPS. Analysts expect that Bioventus Inc. will post 0.4 earnings per share for the current year.

Insider Transactions at Bioventus

In related news, SVP Anthony D’adamio sold 5,904 shares of Bioventus stock in a transaction on Friday, June 21st. The shares were sold at an average price of $5.57, for a total value of $32,885.28. Following the transaction, the senior vice president now owns 95,576 shares in the company, valued at approximately $532,358.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, SVP Anthony D’adamio sold 5,904 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $5.57, for a total transaction of $32,885.28. Following the transaction, the senior vice president now directly owns 95,576 shares in the company, valued at approximately $532,358.32. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John A. Bartholdson acquired 80,000 shares of the stock in a transaction on Friday, August 16th. The stock was bought at an average price of $8.55 per share, with a total value of $684,000.00. Following the transaction, the director now directly owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. The disclosure for this purchase can be found here. Company insiders own 32.90% of the company’s stock.

Hedge Funds Weigh In On Bioventus

Hedge funds have recently modified their holdings of the company. Jump Financial LLC bought a new stake in shares of Bioventus in the fourth quarter worth about $122,000. Hillsdale Investment Management Inc. purchased a new stake in Bioventus in the 4th quarter worth approximately $145,000. Quadrature Capital Ltd bought a new stake in shares of Bioventus in the 4th quarter worth approximately $85,000. GSG Advisors LLC increased its stake in shares of Bioventus by 55.8% during the first quarter. GSG Advisors LLC now owns 26,511 shares of the company’s stock valued at $133,000 after buying an additional 9,500 shares during the period. Finally, LSV Asset Management bought a new position in shares of Bioventus during the first quarter valued at approximately $1,170,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.